PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
BriaCell Therapeutics Corp. (BCT.TO)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINCA10778Y3023
CUSIP10778Y302
SectorHealthcare
IndustryBiotechnology

Highlights

Market CapCA$45.71M
EPS-CA$1.09
EBITDA (TTM)-CA$31.70M
Year RangeCA$2.86 - CA$10.20
Target PriceCA$20.00
Short %0.04%
Short Ratio0.34

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


BriaCell Therapeutics Corp.

Performance

Performance Chart

The chart shows the growth of an initial investment of CA$10,000 in BriaCell Therapeutics Corp., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%0.00%100.00%200.00%300.00%400.00%NovemberDecember2024FebruaryMarchApril
-98.95%
348.40%
BCT.TO (BriaCell Therapeutics Corp.)
Benchmark (^GSPC)

S&P 500

Returns By Period

BriaCell Therapeutics Corp. had a return of -59.62% year-to-date (YTD) and -67.27% in the last 12 months. Over the past 10 years, BriaCell Therapeutics Corp. had an annualized return of -26.88%, while the S&P 500 had an annualized return of 10.55%, indicating that BriaCell Therapeutics Corp. did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date-59.62%6.30%
1 month-7.89%-3.13%
6 months-53.54%19.37%
1 year-67.27%22.56%
5 years (annualized)-36.66%11.65%
10 years (annualized)-26.88%10.55%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-27.56%-17.70%-16.56%
2023-12.52%-29.85%20.68%9.55%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of BCT.TO is 7, indicating that it is in the bottom 7% of the market in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.

The Risk-Adjusted Performance Rank of BCT.TO is 77
BriaCell Therapeutics Corp.(BCT.TO)
The Sharpe Ratio Rank of BCT.TO is 77Sharpe Ratio Rank
The Sortino Ratio Rank of BCT.TO is 77Sortino Ratio Rank
The Omega Ratio Rank of BCT.TO is 88Omega Ratio Rank
The Calmar Ratio Rank of BCT.TO is 1212Calmar Ratio Rank
The Martin Ratio Rank of BCT.TO is 22Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for BriaCell Therapeutics Corp. (BCT.TO) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


BCT.TO
Sharpe ratio
The chart of Sharpe ratio for BCT.TO, currently valued at -0.95, compared to the broader market-2.00-1.000.001.002.003.00-0.95
Sortino ratio
The chart of Sortino ratio for BCT.TO, currently valued at -1.66, compared to the broader market-4.00-2.000.002.004.006.00-1.66
Omega ratio
The chart of Omega ratio for BCT.TO, currently valued at 0.81, compared to the broader market0.501.001.500.81
Calmar ratio
The chart of Calmar ratio for BCT.TO, currently valued at -0.67, compared to the broader market0.001.002.003.004.005.00-0.67
Martin ratio
The chart of Martin ratio for BCT.TO, currently valued at -1.79, compared to the broader market0.0010.0020.0030.00-1.79
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.92, compared to the broader market-2.00-1.000.001.002.003.001.92
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.78, compared to the broader market-4.00-2.000.002.004.006.002.78
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.33, compared to the broader market0.501.001.501.33
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.47, compared to the broader market0.001.002.003.004.005.001.47
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.64, compared to the broader market0.0010.0020.0030.007.64

Sharpe Ratio

The current BriaCell Therapeutics Corp. Sharpe ratio is -0.95. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2024FebruaryMarchApril
-0.95
2.32
BCT.TO (BriaCell Therapeutics Corp.)
Benchmark (^GSPC)

Dividends

Dividend History


BriaCell Therapeutics Corp. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2024FebruaryMarchApril
-99.47%
-2.74%
BCT.TO (BriaCell Therapeutics Corp.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the BriaCell Therapeutics Corp.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the BriaCell Therapeutics Corp. was 99.52%, occurring on Apr 19, 2024. The portfolio has not yet recovered.

The current BriaCell Therapeutics Corp. drawdown is 99.47%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.52%May 2, 20112669Apr 19, 2024
-83.33%Dec 4, 200696Apr 24, 2009218Oct 15, 2010314
-51.72%Oct 18, 201020Nov 15, 2010103Apr 29, 2011123
-9.09%Oct 20, 20061Oct 20, 20065Nov 13, 20066

Volatility

Volatility Chart

The current BriaCell Therapeutics Corp. volatility is 26.48%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%30.00%35.00%NovemberDecember2024FebruaryMarchApril
26.48%
3.28%
BCT.TO (BriaCell Therapeutics Corp.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of BriaCell Therapeutics Corp. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items